BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 27081557)

  • 1. Somatic mosaicism of EPAS1 mutations in the syndrome of paraganglioma and somatostatinoma associated with polycythemia.
    Yang C; Hong CS; Prchal JT; Balint MT; Pacak K; Zhuang Z
    Hum Genome Var; 2015; 2():15053. PubMed ID: 27081557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonmosaic somatic HIF2A mutations associated with late onset polycythemia-paraganglioma syndrome: Newly recognized subclass of polycythemia-paraganglioma syndrome.
    Pang Y; Gupta G; Jha A; Yue X; Wang H; Huynh TT; Li A; Li L; Baker E; Chew E; Feelders RA; Korpershoek E; Zhuang Z; Yang C; Pacak K
    Cancer; 2019 Apr; 125(8):1258-1266. PubMed ID: 30644531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mosaicism in HIF2A-related polycythemia-paraganglioma syndrome.
    Buffet A; Smati S; Mansuy L; Ménara M; Lebras M; Heymann MF; Simian C; Favier J; Murat A; Cariou B; Gimenez-Roqueplo AP
    J Clin Endocrinol Metab; 2014 Feb; 99(2):E369-73. PubMed ID: 24276449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Transgenic Mouse Model of Pacak⁻Zhuang Syndrome with An
    Wang H; Cui J; Yang C; Rosenblum JS; Zhang Q; Song Q; Pang Y; Fang F; Sun M; Dmitriev P; Gilbert MR; Eisenhofer G; Pacak K; Zhuang Z
    Cancers (Basel); 2019 May; 11(5):. PubMed ID: 31091718
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polycythemia and paraganglioma with a novel somatic HIF2A mutation in a male.
    Toyoda H; Hirayama J; Sugimoto Y; Uchida K; Ohishi K; Hirayama M; Komada Y
    Pediatrics; 2014 Jun; 133(6):e1787-91. PubMed ID: 24819565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vascular Changes in the Retina and Choroid of Patients With EPAS1 Gain-of-Function Mutation Syndrome.
    Dmitriev PM; Wang H; Rosenblum JS; Prodanov T; Cui J; Pappo AS; Gilbert MR; Lutty GA; Chan CC; Chew EY; Pacak K; Zhuang Z
    JAMA Ophthalmol; 2020 Feb; 138(2):148-155. PubMed ID: 31876943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel HIF2A mutations disrupt oxygen sensing, leading to polycythemia, paragangliomas, and somatostatinomas.
    Yang C; Sun MG; Matro J; Huynh TT; Rahimpour S; Prchal JT; Lechan R; Lonser R; Pacak K; Zhuang Z
    Blood; 2013 Mar; 121(13):2563-6. PubMed ID: 23361906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A new twist in neuroendocrine tumor research: Pacak-Zhuang syndrome, HIF-2α as the major player in its pathogenesis and future therapeutic options.
    Jochmanova I; Lazurova I
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2014 Jun; 158(2):175-80. PubMed ID: 24781045
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel insights into the polycythemia-paraganglioma-somatostatinoma syndrome.
    Därr R; Nambuba J; Del Rivero J; Janssen I; Merino M; Todorovic M; Balint B; Jochmanova I; Prchal JT; Lechan RM; Tischler AS; Popovic V; Miljic D; Adams KT; Prall FR; Ling A; Golomb MR; Ferguson M; Nilubol N; Chen CC; Chew E; Taïeb D; Stratakis CA; Fojo T; Yang C; Kebebew E; Zhuang Z; Pacak K
    Endocr Relat Cancer; 2016 Dec; 23(12):899-908. PubMed ID: 27679736
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New syndrome of paraganglioma and somatostatinoma associated with polycythemia.
    Pacak K; Jochmanova I; Prodanov T; Yang C; Merino MJ; Fojo T; Prchal JT; Tischler AS; Lechan RM; Zhuang Z
    J Clin Oncol; 2013 May; 31(13):1690-8. PubMed ID: 23509317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumoral EPAS1 (HIF2A) mutations explain sporadic pheochromocytoma and paraganglioma in the absence of erythrocytosis.
    Comino-Méndez I; de Cubas AA; Bernal C; Álvarez-Escolá C; Sánchez-Malo C; Ramírez-Tortosa CL; Pedrinaci S; Rapizzi E; Ercolino T; Bernini G; Bacca A; Letón R; Pita G; Alonso MR; Leandro-García LJ; Gómez-Graña A; Inglada-Pérez L; Mancikova V; Rodríguez-Antona C; Mannelli M; Robledo M; Cascón A
    Hum Mol Genet; 2013 Jun; 22(11):2169-76. PubMed ID: 23418310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chiari Malformation Type 1 in
    Rosenblum JS; Maggio D; Pang Y; Nazari MA; Gonzales MK; Lechan RM; Smirniotopoulos JG; Zhuang Z; Pacak K; Heiss JD
    Int J Mol Sci; 2019 Jun; 20(11):. PubMed ID: 31185588
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional significance of germline EPAS1 variants.
    Dwight T; Kim E; Bastard K; Benn DE; Eisenhofer G; Richter S; Mannelli M; Rapizzi E; Prejbisz A; Pęczkowska M; Pacak K; Clifton-Bligh R
    Endocr Relat Cancer; 2021 Feb; 28(2):97-109. PubMed ID: 33300499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Somatic HIF2A gain-of-function mutations in paraganglioma with polycythemia.
    Zhuang Z; Yang C; Lorenzo F; Merino M; Fojo T; Kebebew E; Popovic V; Stratakis CA; Prchal JT; Pacak K
    N Engl J Med; 2012 Sep; 367(10):922-30. PubMed ID: 22931260
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EPAS-1-related pheochromocytoma/paraganglioma: How common and how aggressive?
    Alzahrani AS; Alswailem M; Buffet A; Alghamdi B; Alobaid L; Alsagheir O; Al-Hindi H; Pacak K
    Endocr Relat Cancer; 2024 May; ():. PubMed ID: 38767322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comprehensive
    Karaghiannis V; Maric D; Garrec C; Maaziz N; Buffet A; Schmitt L; Antunes V; Airaud F; Aral B; Le Roy A; Corbineau S; Mansour-Hendili L; Lesieur V; Rimbert A; Laporte F; Delamare M; Rab M; Bézieau S; Cassinat B; Galacteros F; Gimenez-Roqueplo AP; Burnichon N; Cario H; Van Wijk R; Bento C; Girodon F; Hoogewijs D; Gardie B
    Haematologica; 2023 Jun; 108(6):1652-1666. PubMed ID: 36700397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuraxial dysraphism in
    Rosenblum JS; Cappadona AJ; Argersinger DP; Pang Y; Wang H; Nazari MA; Munasinghe JP; Donahue DR; Jha A; Smirniotopoulos JG; Miettinen MM; Knutsen RH; Kozel BA; Zhuang Z; Pacak K; Heiss JD
    Neurol Genet; 2020 Jun; 6(3):e414. PubMed ID: 32337341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Developmental vascular malformations in EPAS1 gain-of-function syndrome.
    Rosenblum JS; Wang H; Dmitriev PM; Cappadona AJ; Mastorakos P; Xu C; Jha A; Edwards N; Donahue DR; Munasinghe J; Nazari MA; Knutsen RH; Rosenblum BR; Smirniotopoulos JG; Pappo A; Spetzler RF; Vortmeyer A; Gilbert MR; McGavern DB; Chew E; Kozel BA; Heiss JD; Zhuang Z; Pacak K
    JCI Insight; 2021 Mar; 6(5):. PubMed ID: 33497361
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Belzutifan, a Potent HIF2α Inhibitor, in the Pacak-Zhuang Syndrome.
    Kamihara J; Hamilton KV; Pollard JA; Clinton CM; Madden JA; Lin J; Imamovic A; Wall CB; Wassner AJ; Weil BR; Heeney MM; Vargas SO; Kaelin WG; Janeway KA; Perini RF; Zojwalla NJ; Voss SD; DuBois SG
    N Engl J Med; 2021 Nov; 385(22):2059-2065. PubMed ID: 34818480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frequent EPAS1/HIF2α exons 9 and 12 mutations in non-familial pheochromocytoma.
    Welander J; Andreasson A; Brauckhoff M; Bäckdahl M; Larsson C; Gimm O; Söderkvist P
    Endocr Relat Cancer; 2014 Jun; 21(3):495-504. PubMed ID: 24741025
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.